Realm begins Phase II trial of PR022 for atopic dermatitis

Realm Therapeutics plc (LSE:RLM) started a Phase II trial of PR022 to treat adults with mild to moderate atopic dermatitis. Realm expects top-line

Read the full 236 word article

User Sign In